Imugene is an Australian biotechnology company developing cancer immunotherapies, with operations in the U.S. and in Europe.

The company’s key assets are B-cell peptide cancer vaccines

Imugene Ltd’s (ASX:IMU) phase 1 clinical trial data for its B cell peptide cancer vaccine B-Vaxx has been published in the prestigious American Association for Cancer Research journal Clinical Cancer Research.

The title of the article is "Phase 1 Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines emulsified in Montanide ISA 720VG and nor-MDP Adjuvant in Advanced Solid Tumors."

The article is primarily authored by Imugene’s Scientific Advisory Board members Professor Pravin Kaumaya from the Ohio State University and Dr Tanios Bekaii-Saab from the Mayo Clinic.

Two lead cancer vaccine candidates

The company’s key assets are B-lymphocyte or B-cell peptide cancer vaccines that link an immunogenic protein with a B-cell epitope peptide and include an adjuvant to induce the body into producing antibodies against normal self-proteins.

Imugene’s two lead therapeutic vaccine candidates are the HER-Vaxx vaccine and the B-Vaxx vaccine.

HER-Vaxx is an anti-HER2/neu product that has been taken through a successful phase 1b study in 14 gastric cancer patients.

B-Vaxx is also another B-cell peptide cancer vaccine and is designed to treat tumours that over-express the HER2/neu receptor.

Quick facts: Imugene Ltd

Price: 0.035 AUD

ASX:IMU

Market: ASX

Market Cap: $154.91 m

Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said...

Watch

Imugene Ltd (ASX:IMU) chief executive officer Leslie Chong and visiting US Professor Yuman Fong update Proactive on the progress of the company’s remarkable CF33 oncolytic virotherapy technology, which was acquired in July 2019.
Professor Fong is the inventor of the technology and spoke about...